We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Données en vie réelle de l'utilisation du trastuzumab IV dans le carcinome mammaire métastatique HER2-positif.
- Authors
Genevée, T.; Lortal, B.
- Abstract
With the arrival of fixed dose formulation in 2013 and biosimilars in the near future, we wanted to realize an inventory of the use of Trastuzumab IV in real life and evaluate the overall survival (OS) of patients with metastatic breast carcinoma HER2 positive. We analyzed retrospectively epidemiological, pathological, and drug datas of patients in a French Cancer Centre (CLCC). In addition, we determined the median OS and compared the OS of extreme weight/BMI patients. The patient model was a 55-56 years old woman measuring 1.61 m, weighing 65.4 kg. Trastuzumab is mostly used as soon as the tumor status HER2+ is demonstrated, associated with a cytotoxic, docetaxel, or navelbine. Median overall survival is estimated at 44 months. Our population was superimposable to those described in pivotal studies leading to the market authorization of Trastuzumab. Patients overall survival in low/high weights and low/high BMI subgroups showed significant differences with 5% alpha risk.
- Publication
Oncologie (Tech Science Press), 2017, Vol 19, Issue 7/8, p247
- ISSN
1292-3818
- Publication type
Article
- DOI
10.1007/s10269-017-2719-8